Estrogen Complexes Contained in Conjugated Equine Estrogens (CEE): An Overview of Their Structure and Possible Effects on Target Tissue

  • C. Richard Lyttle
  • Michael Dey
Part of the Medical Science Symposia Series book series (MSSS, volume 13)


The basic concept of estrogen action was established many years ago by pioneering studies by Drs. Elwood Jensen and Jack Gorski [1,2]. In this presentation, this model will be reviewed and it will be suggested that several modifications to this model are required, as well as to the way clinicians and scientists think about the mechanism of steroid hormone action. First, data will be presented which suggest the need to rethink how estrogens work and how they interact with the receptor. Secondly, additional data on a new component found within the conjugated equine estrogens (CEE) family will be presented. Third, some speculation about the newer mechanisms that are being explored which can change the way estrogens work will be presented.


Estrogen Receptor Conjugate Equine Estrogen Receptor Conformation Human Estrogen Receptor Estrone Sulfate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jensen EV, Brecher PI, Numata M, Smith S, DeSombre ER. Estrogen interaction with target tissues; two-step transfer of receptor to the nucleus. Methods in Enzymology 1975;36:267–75.PubMedGoogle Scholar
  2. 2.
    Toft D, Gorski J. A receptor molecule for estrogens; isolation from the rat uterus and preliminary characterization. Proc Nat Acad Sci USA 1966;55:1574–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Jensen EV, DeSombre ER. Estrogen-receptor interaction. Science 1973;182:126–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Reese JC, Katzenellenbogen BS. Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: Studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acid Res 1991;23:6595–6602.CrossRefGoogle Scholar
  5. 5.
    Klein-Hitpass L, Tsai SY, Greene GL, Clark JH, Tsai M-J, O’Malley BW. Specific binding of estrogen receptor to the response element. Mol Cell Biol 1989;9:43–49.PubMedGoogle Scholar
  6. 6.
    Sundstrom SA, Komm BS, Xu Q, Boundy V, Lyttle CR. The stimulation of uterine complement component C3 gene expression by antiestrogens. Endo 1990;126:1449–56.Google Scholar
  7. 7.
    Sundstrom SA, Komm BS, Ponce-de-Leon H, Yi Z, Teuscher C, Lyttle CR. Estrogen regulation of tissue-specific expression of complement C3. J Biol Chem 1989;264:16941–47.PubMedGoogle Scholar
  8. 8.
    Baracat E, Haidar M, Lopez, FJ, Pickar, J, Dey M, Negro-Vilar A. Estrogen activity and novel tissue selectivity of Δ8,9 dehydroestrone sulfate in postmenopausal women. JCEM Submitted.Google Scholar
  9. 9.
    Ward RL, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993;22:87–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Colletta AA, et al. Anti-oestrogens induce the secretion of active transforming growth factor β from human fetal fibroblasts. British J Cancer 1990;62:405–9.Google Scholar
  11. 11.
    Turken S, Siris E, Seldin D, Flaster E, Hyman G, Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. Journal of the National Cancer Institute 1989;81(14);1086–89.PubMedCrossRefGoogle Scholar
  12. 12.
    Fan JD, Wagner BL, McDonnell DP. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol Endo 1996;10(12):1605–16.CrossRefGoogle Scholar
  13. 13.
    Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO J 1990;9:2811–18.PubMedGoogle Scholar
  14. 14.
    Tzukeman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionality distinct intermolecular regions. Mol Endo 1994;9:21–30.CrossRefGoogle Scholar
  15. 15.
    McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endo 1995;9:659–69.CrossRefGoogle Scholar
  16. 16.
    Allan GF, Leng X, Tsai S-T, et al. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 1992;267:19513–20.PubMedGoogle Scholar
  17. 17.
    McDonnell DP, Vegeto E, O’Malley BW. Identification of a negative regulatory function for steroid receptors. Proc Natl Acad Sci USA 1992;89:10563–67.PubMedCrossRefGoogle Scholar
  18. 18.
    Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Pro Natl Acad Sci USA 1996;93:5925–30.CrossRefGoogle Scholar
  19. 19.
    Katzenellenbogen BS, Korach KS. A new actor in the estrogen receptor drama-enter ERβ. Endo 1997;138:861–62.Google Scholar
  20. 20.
    Nilsson S, Kuiper G, Gustafsson JA. ERbeta: A novel estrogen receptor offers the potential for new dug development. Trends Endo Metab 1998;9:387–95.CrossRefGoogle Scholar
  21. 21.
    Kuiper GGJM, Shughrue PJ, Merchenthaler I, Gustaffsson JA. The estrogen receptor beta subtype—A novel mediator of estrogen action in neuroendocrine systems. Frontiers Neuroendo 1998;19:253–86.CrossRefGoogle Scholar
  22. 22.
    Gustafsson JA. Therapeutic potential of selective estrogen receptor modulators. Current Opinion Chem Biol 1998;2:508–11.CrossRefGoogle Scholar
  23. 23.
    Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 1994;264:1455–58.PubMedCrossRefGoogle Scholar
  24. 24.
    Cavilles V, Dauvois S, Danielian PS, Parker MG. Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 1994;91:10000–13.CrossRefGoogle Scholar
  25. 25.
    Arnold SF, Obourn JD, Jaffe H, Notides AC. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endo 1994;8:1208–14.CrossRefGoogle Scholar
  26. 26.
    Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson JA. A regulatory role for RIP 140 in nuclear receptor activation. Mol Endo 1998;12:864–81.CrossRefGoogle Scholar
  27. 27.
    Li H, Gomes PJ, Chen JD. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 1997;94:8479–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 1998;273:27645–53.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers and Fondazione Giovanni Lorenzini 1999

Authors and Affiliations

  • C. Richard Lyttle
  • Michael Dey

There are no affiliations available

Personalised recommendations